



*TSX Venture Exchange: CCG  
FOR IMMEDIATE RELEASE*

## **CardioComm Solutions Inc. Engages The Trout Group Specialized New York-based Investor Relations Firm to Lead U.S. Capital Markets Activity**

**VICTORIA, B.C.**, September 22, 2004 – CardioComm Solutions Inc. (TSX-V:CCG) (the "Company", "CardioComm"), is pleased to report that it has engaged The Trout Group LLC, a leading New York based investor relations firm, to facilitate the Company's exposure to US capital markets by developing relationships with portfolio managers, investment bankers and industry analysts in New York and San Francisco. With extensive institutional investor relationships in the United States, Canada and Europe, The Trout Group provides strategic advisory and investor relations services to Life Sciences companies.

"As we continue to see significant increases in revenue and expand upon key business development partnerships within the U.S. market, it is important to begin creating American based investor awareness for our company. We are delighted to be doing so with The Trout Group. We believe that they have the background, industry understanding, and the necessary tools to help broaden our message," said Stephen Martin, President and CEO of CardioComm Solutions Inc.

Jonathan Fassberg, President of The Trout Group, said, "CardioComm Solutions has impressed us with their technology and business model as well as the partnerships they have with some of the leading cardiology companies in the world. We are excited by the prospect of bringing this highly innovative company to some of the savviest Life Sciences investors in the United States."

Pursuant to the engagement, CardioComm will provide compensation to The Trout Group of US\$5,000 per month. In addition, subject to regulatory approval, The Trout Group will receive an option to purchase 300,000 common shares of CardioComm Solutions Inc. at an exercise price of C\$0.23.

### **About The Trout Group**

Since 1995, Trout professionals have advised over 100 public and private companies throughout the US, Canada and Europe with corporate positioning and strategy development, institutional and retail investor outreach, M&A and fundraising support, and market intelligence. Headquartered in New York, The Trout Group also serves clients from satellite offices in San Francisco, Boston, Munich and Tel Aviv.

### **About CardioComm Solutions Inc:**

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its

technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors  
of CardioComm Solutions Inc:

“Stephen Martin”

---

Stephen R. Martin, President & CEO

***For investor information, please Contact:***

***Derek Sutherland***  
***[IR@CardioComm.com](mailto:IR@CardioComm.com)***  
***Call: 416-832-0442***

***The Trout Group***  
***Tim Ryan***  
***[tryan@troutgroup.com](mailto:tryan@troutgroup.com)***  
***Call: 212-477-9007 x24***

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.